RBC Capital Cuts Johnson & Johnson (JNJ) Price Target to $280

RBC Capital has reaffirmed its Outperform rating on Johnson & Johnson, adjusting the price target to $280, a 9.67% upside from the current price.

By EarningsIQ Research Desk · Published Oct 15, 2026, 9:18 PM EDT · Updated Oct 16, 2026, 1:55 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital cut its price target on Johnson & Johnson ($JNJ) to $280 from $290 on October 14, 2026, and rates the stock "Outperform".

Since the rating, $JNJ is up 0.7% to date (from the $253.91 close on Oct 14, 2026).

JNJ Johnson & Johnson

$255.56 +25.23% year to date

Daily close · Oct 16, 2026

Key Points

On October 14, 2026, RBC Capital reiterated its Outperform rating on Johnson & Johnson (NYSE: JNJ) and set a price target of $280, down from $290.
RBC Capital's $280 price target implies 9.67% upside from Johnson & Johnson's ($JNJ) current $255.31 share price.
As of October 16, 2026, JNJ shares were recently trading around $255.31, which is below the firm’s target and also below the 50-day moving average by about 3.8%.
The stock has a market cap of approximately $610.4 billion and has a trailing twelve-month revenue of about $99.3 billion.

Get $JNJ trade alerts by text

We text you when insiders, Congress or big funds trade $JNJ. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures

RBC Capital has reiterated its Outperform rating on Johnson & Johnson (NYSE: JNJ) and set a new price target of $280, down from $290. This update came on October 14, 2026, as part of their regular assessment of the healthcare giant.

RBC Capital's Call on Johnson & Johnson

RBC Capital maintains an Outperform rating on Johnson & Johnson, adjusting the price target from $290 to $280. This reflects a slight revision in their expectations for the stock's performance.

Other Institutional Activity in Johnson & Johnson

Several other institutional investors have also been active with their positions in Johnson & Johnson. Blackrock Inc. trimmed its holdings by 1,280,271 shares, holding a total of 212,098,264 shares valued at about $54.2 billion. Vanguard Capital Management LLC added 626,400 shares, bringing its total to 157,226,374 shares worth approximately $40.2 billion. State Street Corporation increased its stake by 293,661 shares, ending with 133,776,025 shares valued at around $34.2 billion. Vanguard Portfolio Management LLC grew its holdings by 857,431 shares, totaling 64,370,816 shares worth about $16.4 billion. Geode Capital Management, LLC decreased its holdings by 76,912 shares, now holding 59,086,417 shares valued at roughly $15.1 billion.

Johnson & Johnson Stock Up 0.6%

As of October 16, 2026, Johnson & Johnson shares were recently trading around $255.31. This price is below the firm’s updated target of $280 and about 3.8% lower than its 50-day moving average. The stock is also about 9.2% below its 52-week high of $281.07, yet it remains 38.3% above its 52-week low of $184.66.

12-month forecast

$JNJ price target

Johnson & Johnson daily closes and this analyst's $280 target. Not advice.

Recent Earnings

For the trailing twelve months, Johnson & Johnson reported revenue of approximately $99.3 billion and an earnings per share (EPS) of $6.59. The company has shown a year-over-year revenue growth of 5.9%, with a net margin of 16.2%. The next earnings report is scheduled for January 26, 2027.

Insider Buying and Selling at Johnson & Johnson

Recent insider activity includes several sales. Elizabeth Forminard, an Officer, sold 15,918 shares valued at about $4.1 million on August 6, 2026. CEO Joaquin Boix Duato sold 123,291 shares worth approximately $32.2 million on August 13, 2026. Jennifer L. Taubert, another Officer, sold 15,000 shares at an average price of $263.36, totaling about $3.95 million on August 17, 2026. Timothy Schmid, also an Officer, sold 33,597 shares for around $9.2 million on September 2, 2026.

Analysts Set New Price Targets

On October 14, 2026, RBC Capital reiterated its Outperform rating on Johnson & Johnson with a new price target of $280, down from $290. Other analysts have also weighed in; for example, Leerink Partners maintained an Outperform rating with a target of $272, while Wells Fargo kept an Overweight rating with a target of $275. The consensus among 22 analysts is a Buy recommendation with a mean price target of about $279.41.

About Johnson & Johnson

Johnson & Johnson, based in New Brunswick, NJ, is a leading healthcare company involved in the research, development, manufacture, and sale of a wide range of healthcare products. The company operates in two main segments: Innovative Medicine and MedTech. This latest analyst update highlights the firm's ongoing interest in the stock despite recent adjustments to price targets.

Bottom Line

Investors should keep an eye on Johnson & Johnson's upcoming earnings report on January 26, 2027, as well as any further updates from analysts. RBC Capital's latest target adjustment reflects their continued confidence in the company's long-term potential, despite the recent price revisions.